Back to Clinical Trials
N/ARecruiting

Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure

Sponsored by VisCardia Inc.

About this study

RECOVER HF is a clinical study designed to evaluate the safety and efficacy of Synchronized Diaphragmatic Stimulation delivered using the VisONE System in the treatment of patients with heart failure.

Symptomatic Diaphragmatic Stimulation (SDS) is a novel extra-cardiac device for patients who have symptomatic heart failure. Elevated intracardiac pressures are the hallmark of heart failure (HF) and a key pathological driver of disease progression and limited exertional capacity. The degree of cardiac pressure elevation is determined by preload, afterload, and pericardial restraint. The pericardium restrains the heart, and the degree of restraint is determined by the pericardial structure itself and the intrathoracic pressure. This aspect of HF pathophysiology is among the fundamental drivers behind the SDS therapy concept. SDS induces a temporal modulation of intrathoracic pressure.. When synchronized with the cardiac cycle, SDS may improve cardiac filling, cardiovascular pressure condit…

Where this study is enrolling (2)

  • Saint Francis Hospital

    Tulsa, Oklahoma

    Call 918-494-8500

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • University of Pennsylvania

    Philadelphia, Pennsylvania

    I'm interested
Who can participate

Inclusion criteria

  • ✓NYHA classes II/III on optimal Guideline Directed Medical Therapy (GDMT)
  • ✓QRS duration ≤ 130 ms
  • ✓EF≤ 40%

Exclusion criteria

  • ✕Baseline 6 minute walk test \> 500 meters or \< 200 meters
  • ✕NT-proBNP\< 250 if on loop diuretics, or NT-proBNP \< 500 if not on loop diuretics
  • ✕Supine resting heart rate \> 140 bpm
  • ✕Systolic blood pressure \< 80 mmHg or \> 170 mmHg
  • ✕Serum creatinine \> 2.5 mg/dL
  • ✕Serum hepatic function 3x ULN
  • ✕Any of the following within the previous 3 months: unstable angina, AMI, CABG, PTCA, CVA/TIA, persistent AF (\> 24 hours), symptomatic NSVT or DCCV
  • ✕Any inotropic drug treatment within the previous 3 months
  • ✕Bradycardia (heart rate \< 50 beats/min), atrial arrhythmias with rates \> 100 beats/min, sustained ventricular tachycardia or frequent ventricular ectopy \>10% present during screening
  • ✕Significant uncontrolled symptomatic bradyarrhythmia, atrial fibrillation, unstable ventricular arrhythmias or frequent ventricular ectopy \> 10% documented within the previous 3 months
  • ✕Reversible non-ischemic cardiomyopathy
  • ✕Valvular disease requiring intervention within the next 12 months or presence of significant valve disease as determined by the site cardiologist as:
  • ✕1. Greater than mild mitral valve stenosis
  • ✕2. Greater than moderate mitral valve regurgitation
  • ✕3. Greater than mild tricuspid valve stenosis
  • ✕4. Greater than moderate-severe tricuspid valve regurgitation
  • ✕5. Greater than moderate aortic stenosis
  • ✕6. Greater than moderate aortic regurgitation
  • ✕7. Greater than mild-moderate pulmonic stenosis
  • ✕8. Greater than moderate pulmonic regurgitation
  • ✕Severe primary pulmonary disease, including pulmonary arterial hypertension. PAP sys \>70 mmHg at rest
  • ✕Severe COPD, other respiratory or lung diseases where FEV \< 50%
  • ✕Presence of more than small pleural effusion or history of pleural drainage within the previous 6 months
  • ✕Known history of diaphragmatic paralysis or suspicion confirmed by unilateral or bilateral elevation of the diaphragm on chest x-ray
  • ✕Pericardial disease
  • ✕Diabetic neuropathy
  • ✕Existing diaphragmatic stimulation for respiration assist
  • ✕Present LVAD, Baroreflex Activation Therapy, Cardiac Contractility Modulation or interatrial shunt devices; temporary mechanical cardiac assist devices (current or within the previous 3 months); or CRT that is indicated or implanted and functional
  • ✕Contraindications to laparoscopic access to the diaphragm, as determined by the implanting physician
  • ✕Known intra-abdominal pathology which could increase the risk of laparoscopic access to the diaphragm.
  • ✕Previous open laparotomy within 1 year
  • ✕Previous thoracic or abdominal organ transplant
  • ✕Drug induced immuno-suppression
  • ✕Body mass index \> 40
  • ✕Enrollment in a concurrent investigation / clinical study
  • ✕Having a life expectancy of \<1 year due to any condition
  • ✕Pregnant or planning a pregnancy during the study period
  • ✕Known allergies to implantable device materials
  • ✕History of systemic infection requiring the use of intravenous antibiotics within the previous 3 months

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.